CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-31 | Patel Sushil Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 13,400 | ||
| 2024-10-14 | Kelsey Stephen Michael See Remarks | Option exercise 10b5-1 | +16,666 | $4.09 | $68K | 281,074 |
| 2024-10-14 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −14,056 | $49.38 | $694K | 267,018 |
| 2024-10-14 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −2,610 | $50.08 | $131K | 264,408 |
| 2024-10-14 | Kelsey Stephen Michael See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,666 | 23,332 | ||
| 2024-10-11 | Horn Margaret A Chief Operating Officer | Option exercise 10b5-1 | +44,631 | $4.09 | $183K | 176,951 |
| 2024-10-11 | Horn Margaret A Chief Operating Officer | Option exercise 10b5-1 | +5,369 | $4.09 | $22K | 182,320 |
| 2024-10-11 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −50,000 | $50.34 | $2.5M | 132,320 |
| 2024-10-11 | Horn Margaret A Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −44,631 | 0 | ||
| 2024-10-11 | Horn Margaret A Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,369 | 97,382 | ||
| 2024-10-11 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +30,000 | $4.09 | $123K | 330,170 |
| 2024-10-11 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −30,000 | $50.36 | $1.5M | 300,170 |
| 2024-10-11 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 241,229 | ||
| 2024-10-11 | Anders Jack Chief Financial Officer | Option exercise 10b5-1 | +10,000 | $2.68 | $27K | 108,932 |
| 2024-10-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −10,000 | $50.30 | $503K | 98,932 |
| 2024-10-11 | Anders Jack Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 2,814 | ||
| 2024-10-11 | Cislini Jeff General Counsel | Option exercise 10b5-1 | +6,000 | $36.57 | $219K | 51,634 |
| 2024-10-11 | Cislini Jeff General Counsel | Sale 10b5-1 | −6,000 | $50.17 | $301K | 45,634 |
| 2024-10-11 | Cislini Jeff General Counsel | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 36,000 | ||
| 2024-10-08 | Weber Barbara Director | Sale 10b5-1 | −5,200 | $48.02 | $250K | 13,065 |
Page 21 of 29 · 569 trades